These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 16763827

  • 1. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [Abstract] [Full Text] [Related]

  • 2. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C, Barrail A, Goujard C, Taburet AM.
    Clin Pharmacokinet; 2005 Oct; 44(10):1035-50. PubMed ID: 16176117
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):59-66. PubMed ID: 23392467
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM, Robidou P, Jaillon P.
    Ther Drug Monit; 2005 Apr 01; 27(2):186-92. PubMed ID: 15795650
    [Abstract] [Full Text] [Related]

  • 11. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Gingelmaier A, Weizsäcker K, Kabeya K, Taylor G, Rockstroh J, Lambert J, Moltó J, Wyen C, Sadiq ST, Ivanovic J, Giaquinto C, Burger D, PANNA network.
    Antivir Ther; 2015 Apr 01; 20(1):57-64. PubMed ID: 24992294
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Droste JA, Kearney BP, Hekster YA, Burger DM.
    J Acquir Immune Defic Syndr; 2006 Jan 01; 41(1):37-43. PubMed ID: 16340471
    [Abstract] [Full Text] [Related]

  • 14. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeño S, Valero S, Negredo E, Clotet B.
    Ther Drug Monit; 2010 Feb 01; 32(1):93-6. PubMed ID: 20040897
    [Abstract] [Full Text] [Related]

  • 15. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
    Wang X, Boffito M, Zhang J, Chung E, Zhu L, Wu Y, Patterson K, Kashuba A, Tebas P, Child M, Mahnke L, Bertz R.
    AIDS Patient Care STDS; 2011 Sep 01; 25(9):509-15. PubMed ID: 21770762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.
    Antivir Ther; 2013 Sep 01; 18(7):931-40. PubMed ID: 23963204
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E, Raffi F, Biron C, Allavena C, Jolliet P.
    Fundam Clin Pharmacol; 2008 Feb 01; 22(1):101-4. PubMed ID: 18251726
    [Abstract] [Full Text] [Related]

  • 20. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N.
    Drugs Today (Barc); 2008 Feb 01; 44(2):103-32. PubMed ID: 18389089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.